SPOTLIGHT: Analysts ponder Cervarix delay

There's been a considerable number of post mortems on the FDA's decision to delay a decision on GlaxoSmithKlines's Cervarix, a cervical cancer vaccine that is already approved in Europe and has the capacity to become a blockbuster therapy in competition with Merck's Gardasil. Motley Fool's Brian Lawler is betting that the European Medicine Agency's green light indicates only a small hold-up for Cervarix. Glaxo added considerably to the uncertainty around the delay when it declined to spell out exactly what the regulators want to know. In the meantime, though, Gardasil has gained even more time to establish itself as the leader in the HPV vaccine race. Article

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.